동의신경정신과학회지 (Journal of Oriental Neuropsychiatry)

  • 제35권3호
  • /
  • Pages.217-229
  • /
  • 2024
  • /
  • 1226-6396(pISSN)
  • /
  • 2234-4942(eISSN)
대한한방신경정신과학회 (The Korean Society of Oriental Neuropsychiatry)
권호 표지
DOI QR코드

DOI QR Code

항우울제와 한약제제의 병용투여지침 개발-에스시탈로프람과 보험 4종 한약제제를 중심으로

A Study on the Development of Guideline for Co-Administration of Four Types of Herbal Medicine and Escitalopram

  • 이도은 (원광대학교 한의과대학 한방신경정신과학교실) ;
  • 고경진 (원광대학교 한의과대학 한방신경정신과학교실) ;
  • 김영우 (동국대학교 한의과대학 방제학교실) ;
  • 김춘옥 (연세대학교 세브란스병원 임상약리학교실) ;
  • 강형원 (원광대학교 한의과대학 한방신경정신과학교실)
  • Do-Eun Lee (Department of Korean Neuropsychiatry, College of Korean Medicine, Wonkwang University) ;
  • Kyeong Jin Ko (Department of Korean Neuropsychiatry, College of Korean Medicine, Wonkwang University) ;
  • Young-Woo Kim (Department of Herbal Formula, College of Korean Medicine, Dongguk University) ;
  • Choon Ok Kim (Department of Clinical Phamacology, Severance Hospital, Yonsei University Health System) ;
  • Hyung Won Kang (Department of Korean Neuropsychiatry, College of Korean Medicine, Wonkwang University)
  • 투고 : 2024.09.21
  • 심사 : 2024.09.25
  • 발행 : 2024.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives: To develop guidelines for concomitant use of four herbal medicines (Gamisoyosan, Banhasasimtang, Ojeoksan, and Bojungikgitang) with escitalopram. Methods: A guideline development team was assembled and relevant prior research was systematically reviewed to gather evidence. The potential for drug interactions was evaluated by analyzing changes in pharmacokinetic parameters. Safety was assessed through the analysis of adverse drug reactions associated with combined use. Recommendations and concomitant administration guidelines were formulated through a consensus process. Results: No significant drug interactions were identified between the four herbal medicines and escitalopram, indicating no need for dosage adjustment of escitalopram. However, it is recommended to monitor potential adverse reactions during concurrent use. Conclusions: This study provides recommendations for combined use of four herbal medicines covered by domestic insurance combined with escitalopram. Further research on interactions between antidepressants and herbal medicine is necessary to refine and enhance concomitant administration guidelines.

키워드

과제정보

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: RS-2020-KH093754).

참고문헌

  1. Bains N, Abdijadid S. Major Depressive Disorder. Treasure Island (FL): StatPearls. 2023.
  2. Mathers CD, Loncar D, Samet J. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. https://doi.org/10.1371/journal.pmed.0030442
  3. Marvel CL, Paradiso S. Cognitive and neurological impairment in mood disorders. Psychiatr Clin North Am. 2004;27(1):19-36, vii-viii. doi:10.1016/S0193-953X(03)00106-0
  4. Knight MJ, Baune BT. Cognitive dysfunction in major depressive disorder. Curr Opin Psychiatry. 2018;31:26-31. https://doi.org/10.1097/YCO.0000000000000378
  5. Choi MK, Kim KI. Symptoms of depression in Koreans and Japanese: A cross-cultural study. Mental Health Research. 1996;15:104-14.
  6. The Society of Korean Medicine Neuropsychiatry. Clinical practive guideline of Korean Medicine, Depression. Seoul: National Institute for Korean Medicine Development; 2024. 35 p. Report No.: 11-B554036-000055-01.
  7. The Textbook Compilation Committee of Neuropsychiatry of Korean Medical Schools in Nation. The Neuropsychiatry of Oriental medicine. Third edition. Seoul: JipmoonDang. 2016;249-476.
  8. The Society of Korean Medicine Neuropsychiatry. Clinical Practive Guideline of Korean Medicine, Depression. Seoul: National Institute for Korean Medicine Development; 2024. 162-74 p. Report No.: 11-B554036-000055-01.
  9. Edinoff AN, Akuly HA, Hanna TA, et al. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int. 2021;13(3):387-401. https://doi.org/10.3390/neurolint13030038
  10. Ministry of Food and Drug Safety [Internet]. Drug Safety [cited 2022 Aug 20]. Available from: https://nedrug.mfds.go.kr/index
  11. Kim ST. HIRA big data Brief Volume 2, Issue 1. Gangwon: Health Insurance Review & Assessment Service. 2018: 41-8.
  12. von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos. 2001;29(8):1102-9.
  13. Noehr-Jensen L, Zwisler ST, Larsen F, Sindrup SH, Damkier P, Brosen K. Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. Clin Pharmacol Ther. 2009;86:626-33. https://doi.org/10.1038/clpt.2009.154
  14. Noehr-Jensen L, Zwisler ST, Larsen F, et al. Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. Eur J Clin Pharmacol. 2009;65(9):887-94. https://doi.org/10.1007/s00228-009-0657-0
  15. Pharmacy Information Center [Internet]. c2000. Lexapro Tab. 5 mg drug information [cited 2022 Aug 20]. Available from: https://www.health.kr/searchDrug/result_drug.asp?drug_cd=A11AOOOOO5475
  16. Jung YS, Jin BH, Choi JE, Park MS, Kim YW, Kang HW, Cho S, Kim CO. Assessment of Pharmacokinetic Effects of Herbal Medicines on Escitalopram. Ther Clin Risk Manag. 2024;20:151-60. https://doi.org/10.2147/TCRM.S448090
  17. Cho SY, Kim YS, Jang BY, Kim EJ, Han SH, Chae JW, Park MS, Shin SW, Park SH. The Development Guidance of Co-administration Guideline for Herbal Medicine and Chemical Drug. Seoul: National Institute for Korean Medicine Development; 2022. Report No.: 11-B554036-000055-01.
  18. Food and Drug Administration clinical pharmacology. Clinical drug interaction studies-cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. USA:FDA. 2020:1-27.
  19. Son YW. Drug interaction research and labeling guidelines. Seoul: Ministry of Food and Drug Safety. 2015:1-37.
  20. FDA [Internet]. - Approval review of Lexapro: Medical review [cited 2022 Aug 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf
  21. Pharmacy Information Center [Internet]. c2000. Hanpoong Gamisoyosan Soft Extract drug information [cited 2022 Aug 20]. Available from: https://www.health.kr/searchDrug/result_drug.asp?drug_cd=2018101200005
  22. Kim YH, Kim JY, Kwon OJ, Jung SY, Joung JY, Yang CS, Lee JH, Cho JH, Son CG. Efficacy of a Traditional Herbal Formula, Banha-Sasim-Tang in Functional Dyspepsia Classified as Excess Pattern. Front Pharmacol. 2021;12: 698887. https://doi.org/10.3389/fphar.2021.698887
  23. Pharmacy Information Center [Internet]. c2000. Hanpoong Ojeoksan Soft Ext. drug information [cited 2022 Aug 20]. Available from: https://www.health.kr/searchDrug/result_drug.asp?drug_cd=2015080300008
  24. Pharmacy Information Center [Internet]. c2000. Hanpoong Bojungikgitang Soft Ext. drug information [cited 2022 Aug 20]. Available from: https://www.health.kr/searchDrug/result_drug.asp?drug_cd=2018101200007